RxDoctor Payments Data

Daniel Robertshaw, MD

Urology · Fairfield, OHNPI 1881856482

Payments from drug & device makers

$7,119in general payments, 2019–2025

Across 334 payments — averaging $21.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$1K
  • Astellas Pharma US Inc$996
  • Johnson & Johnson$995
  • Coloplast$599
  • Teleflex LLC$309
  • Sumitomo Pharma America, Inc.$300
  • plus $3K from 30 others

What the payments were for

  • Travel & lodging$1963%
  • Food & beverage$6,25788%
  • Education$6669%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,119 in reported general payments places this provider in the 70th percentile of 485 urology providers in Ohio.

See all urology providers in Ohio

Medicare billing

Part B allowed, 2024
$282,563
Medicare patients
703
Services billed
7,619

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OrgovyxRelugolix42$127,030
MyrbetriqMirabegron169$119,612
GemtesaVibegron112$75,767
Tamsulosin Hcl1,049$13,753
Mirabegron ErMirabegron16$8,839
Finasteride602$6,213
Potassium Citrate ErPotassium Citrate43$4,893
Solifenacin Succinate55$4,461
Testosterone Cypionate85$3,778
Tolterodine Tartrate ErTolterodine Tartrate20$2,549
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst66$2,123
Oxybutynin Chloride ErOxybutynin Chloride44$1,146
Desmopressin Acetate18$985
Cabergoline11$852
Bicalutamide12$505

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$300$202,797154 claims
Astellas Pharma US IncMyrbetriq$996$119,612169 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 485 urology providers in Ohio.

Other urology in Fairfield

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →